Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443074 | 1.00 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1CYP1A2CYP3A4 | |
| SCHEMBL12581170 | 1.00 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1CYP1A2CYP3A4 | |
| SCHEMBL2026420 | 0.79 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3R1CYP1A2CYP3A4 | |
| SCHEMBL2026458 | 0.77 | TNKS (0.43) | PIK3CGPIK3CDPIK3CA | |
| SCHEMBL2024043 | 0.72 | TNKS (0.41) | PIK3CG | |
| SCHEMBL2028811 | 0.71 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CA | |
| SCHEMBL2023271 | 0.68 | GRM2 (0.54) | PIK3CG | |
| SCHEMBL2024082 | 0.67 | TNKS (0.43) | PIK3CG | |
| SCHEMBL22012867 | 0.66 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3R1PIK3CA | |
| SCHEMBL31497525 | 0.66 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PIK3CG 1735/4885PIK3CD 1029/4885PIK3R1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.